ADmit Therapeutics is developing a diagnostic test that identifies biomarkers unrelated to β-amyloid and tau for the early detection of Alzheimer's disease. This technology aims to facilitate timely diagnosis, enabling earlier intervention and improved patient outcomes.
Funding
$37.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CCFounders
Product
Problem
Current diagnostic methods for Alzheimer's disease often rely on detecting β-amyloid and tau, which may not identify the disease in its early stages when intervention is most effective. A lack of early detection methods hinders timely diagnosis and delays potential treatments that could improve patient outcomes.
Solution
ADmit Therapeutics is developing the MAP-AD® Test, an in-vitro diagnostic solution designed for the early prognosis of Alzheimer's disease. The test utilizes Next Generation Sequencing and Machine Learning techniques to analyze novel epigenetic biomarkers in mitochondrial DNA, independent of β-amyloid and tau detection. By associating the biology of the disease, specifically mitochondrial dysfunction, with cognitive changes, the MAP-AD® Test aims to predict the progression of mild cognitive impairment to Alzheimer's dementia years before traditional methods. This early prediction enables timely interventions and optimizes patient selection for clinical trials, representing a step toward personalized and precision medicine in Alzheimer's care.
Target Audience
The primary target audience includes clinicians, neurologists, and researchers focused on early detection and personalized treatment strategies for Alzheimer's disease, as well as pharmaceutical companies conducting clinical trials.
Features
- Utilizes Next Generation Sequencing (NGS) to analyze mitochondrial DNA methylation patterns.
- Employs Machine Learning algorithms to predict the progression of mild cognitive impairment to Alzheimer's dementia.
- Focuses on biomarkers non-related to β-amyloid nor tau.
- Integrates analysis of novel blood-based biomarkers with key risk factors like ApoE genotype and age.
- Includes neurophysiological evaluation for a comprehensive assessment.
- Provides a prognostic assessment of the progression from mild cognitive impairment to Alzheimer's dementia.
- Aims to obtain CE marking and approval for clinical use.
- ISO 13485 certified.
- CAP accredited.